Interrogating gynaecological cancer cell metabolism at different oxygen tensions reveals simvastatin as metabolic regulator.

Earlier this month at the Keystone Symposia, Hypoxia: From Basic Mechanisms to Therapeutics, Dr Ayse Latif (pictured below) from the University of Manchester presented a poster entitled “Interrogating gynaecological cancer cell metabolism at different oxygen tensions reveals simvastatin as metabolic regulator”.

The poster describes the background of the study
as follows:Ayse Latif Keystone

Around 200,000 new cases of gynaecological cancers are diagnosed in Europe every year. Potentially 75% of these cancers could benefit from improved treatment regimes. Gynaecological cancer cells have an increased glycolysis rate and lactate concentration which have been suggested to predict increased likelihood of metastasis, resistance to therapy and reduced survival in patients. Lactate transport in cancer cells is carried out by members of the monocarboxylate transporter (MCT) family, notably MCT1/4. Thus, we hypothesized that pharmacologic inhibition of MCTs could improve treatment outcome by reducing glycolytic potential of these tumour cells… (To continue reading, click here).

Researchers at the University of Manchester used a Whitley i2 Instrument Workstation, housing a Seahorse XF Analyzer, connected to a Whitley H35 HEPA Hypoxystation. This allowed for the preparation of cell lines under hypoxic conditions and their subsequent transfer to the i2 for analysis in a CO2 free and controlled temperature environment without exposure to ambient conditions.

 

 

 

i2 Workstation Testimonial Video

In this video – the latest in our series of customer testimonials – Dr Ayse Latif, Faculty of Medical and Human Sciences, University of Manchester, discusses her current research of exploiting tumour cell energy metabolism in order to improve gynaecological cancer treatments.

Dr Latif uses both a H35 HEPA Hypoxystation and an i2 Instrument Workstation. Whilst cells are initially incubated in the H35, they are then moved into the i2 via the Whitley Transfer Tunnel without exposure to ambient conditions, where they can be studied with a Seahorse XF Analyzer.

The i2 was designed to meet the exact requirements  of Seahorse Bioscience, meaning that the combination of this workstation and a Seahorse XF Analyzer permits simultaneous, real-time analysis of mitochondrial respiration and glycolysis in mammalian cells under precisely controlled conditions.

H35 HEPA Testimonial Video

In this video, Dr Michael Cross from the MRC Centre for Drug Safety Science, University of Liverpool, discusses his current research involving the incubation of cardiac spheroids.

Dr Cross uses a Whitley H35 HEPA Hypoxystation, and explains the benefit of the HEPA filtration system in providing a sterile environment for the prolonged culture of cells in physiologically relevant conditions.

For more information about Don Whitley Scientific’s unique HEPA filter, click here.

 

 

Fast Growing Hypoxia Technology Company Strengthens Resources

Burga Kalz Fuller

Don Whitley Scientific announce a key new appointment at their US distributor, HypOxygen (Frederick, MD, USA). Burga Kalz Fuller, PhD has joined the firm to further enhance their penetration of the Hypoxystation hypoxic workstation and related products into the growing field of mammalian cell based hypoxia research.

Burga comes with a wealth of experience within the life sciences industry, having spent the last ten years working with technology suppliers both in Europe and the United States where she was instrumental in the technical supervision of product and equipment development and marketing strategies.

Burga joins HypOxygen as Product Manager to continue HypOxygen’s recent success in providing state of the art hypoxic workstations that lead the way in advancing scientific research and innovation.

Burga comments, “I am excited to start a new challenge with HypOxygen and look forward to working with the team. The range of Whitley HEPA Hypoxystations will play a critical role in furthering advances in the fields of cancer and regenerative medicine research due to the wealth of special features for ultra-clean, precisely controlled physiological atmosphere that make it truly special. I am fortunate to be joining such a respected company that prides itself on providing industry leading technologies to the growing fields of tissue culture research and hypoxia.”

Jason Cadle, National Sales Manager at HypOxygen, said “Burga’s wealth of molecular cell biology experience and industry knowledge has already made her a key addition to the HypOxygen family. We view her appointment as a sign of our commitment to being the leading company in our industry. Our new innovations and the increasing demand from researchers led us to look for an addition to our team who will fit in with our ethos of innovation and exceptional service. It is very fortunate that we were able to find someone of Burga’s caliber to act in this capacity. I’m confident that Burga will play a key role in providing and implementing high quality technical solutions for our clients.”

Paul Walton, Managing Director of Don Whitley Scientific, added “Burga’s appointment is great news for the Whitley Hypoxystation range of products as we improve and expand the range. Having Burga on the team at HypOxygen will improve our international presence in terms of the service we can provide to all our distributors worldwide.”